title: MRD levels during the first months of treatment indicate relapses in children with t(12;21)-positive ALL.
authors.forename: K
authors.initials: K
authors.lastname: Fasching
authors.forename: M
authors.initials: M
authors.lastname: König
authors.forename: K
authors.initials: K
authors.lastname: Hettinger
authors.forename: G
authors.initials: G
authors.lastname: Mann
authors.forename: H
authors.initials: H
authors.lastname: Gadner
authors.forename: O A
authors.initials: OA
authors.lastname: Haas
authors.forename: E R
authors.initials: ER
authors.lastname: Panzer-Grümayer
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism*; D002648:Child; D002675:Child, Preschool; D002881:Chromosomes, Human, Pair 12; D002891:Chromosomes, Human, Pair 21; D050676:Core Binding Factor Alpha 2 Subunit; D006801:Humans; D018365:Neoplasm, Residual / Q000235:genetics / Q000378:metabolism*; D015514:Oncogene Proteins, Fusion / Q000378:metabolism*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics / Q000378:metabolism* / Q000517:prevention & control; D011946:Receptors, Antigen / Q000235:genetics; D012008:Recurrence; D014178:Translocation, Genetic; D000097764:ETS Translocation Variant 6 Protein
chemical_list: D014408:Biomarkers, Tumor; D050676:Core Binding Factor Alpha 2 Subunit; D015514:Oncogene Proteins, Fusion; D011946:Receptors, Antigen; C102421:TEL-AML1 fusion protein; D000097764:ETS Translocation Variant 6 Protein